Aspriant Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 M
- Revenue Growth -39.58%
- Profit Growth -92.56%
- Ebitda -82.27%
- Net Worth 4.31%
- Total Assets -17.07%
About Aspriant Pharmaceuticals
Aspriant Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 January 2015 and has a history of Ten years and one month. Its registered office is in Washim, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.00 M.
Akash Katekar and Dipali Gote serve as directors at the Company.
Company Details
- Location
Washim, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233MH2015PTC260715
- Company No.
260715
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Aspriant Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akash Katekar  | Director | 23-Oct-2020 | Current |
| Dipali Gote | Director | 23-Oct-2020 | Current |
Financial Performance of Aspriant Pharmaceuticals.
Aspriant Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 39.58% decrease. The company also saw a substantial fall in profitability, with a 92.56% decrease in profit. The company's net worth moved up by a moderate rise of 4.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aspriant Pharmaceuticals?
Unlock access to Aspriant Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹3.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 May 2023 | Others | ₹3.00 M | Open |
How Many Employees Work at Aspriant Pharmaceuticals?
Unlock and access historical data on people associated with Aspriant Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aspriant Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aspriant Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
